Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2433Neoplasms 1842Carcinoma, Non-Small-Cell Lung 1609Prostatic Neoplasms 1312Colorectal Neoplasms 1144Lung Neoplasms 991Neoplasm Metastasis 835Multiple Myeloma 800Leukemia, Myeloid, Acute 778Ovarian Neoplasms 685Pancreatic Neoplasms 671Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Carcinoma, Hepatocellular 570Recurrence 568Brain Neoplasms 528Glioblastoma 519Stomach Neoplasms 503Head and Neck Neoplasms 502Triple Negative Breast Neoplasms 473Lymphoma 461Uterine Cervical Neoplasms 457Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 421Lymphoma, Non-Hodgkin 390Endometrial Neoplasms 386Sarcoma 369Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 356Lymphoma, Follicular 356

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hormone Sensitive Prostate Cancer × 1 year × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡